Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMS203
- Development stage
- Phase 2
- Lead developer
- Shandong Lukang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CMS203 is a small molecule phosphodiesterase type 5 (PDE5) inhibitor being developed for the treatment of erectile dysfunction. The drug is a collaborative development project between Shandong Lukang Pharmaceutical, Jinan Meiluwei Biotechnology, and Shanghai Zhongtuo Pharmaceutical. CMS203 works by inhibiting the PDE5 enzyme, which is responsible for the degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. By maintaining higher levels of cGMP, the drug promotes smooth muscle relaxation and increases blood flow to the penis, facilitating an erection in response to sexual arousal. It is designed to offer a potent and potentially more selective profile compared to first-generation PDE5 inhibitors.
02
Targets
PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on CMS203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMS203.